Accès ouvert
2025
article
OpenAlex
Paul Edison, Grazia Daniela Femminella, Craig Ritchie, Joseph Nowell et autres
Liraglutide, a glucagon-like peptide 1 (GLP-1) agonist and antidiabetic drug, has shown neuroprotective effects in animal models. In this study, we aimed to evaluate the safety and efficacy of liraglutide in mild to moderate Alzheimer's disease syndrome. 'Evaluating liraglutide in Alzheimer's disease' …
gb, cn, dk, nl
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Edison P, Grazia Daniela Femminella, C Ritchie, J. Nowell et autres
© The Author(s) 2025.Liraglutide, a glucagon-like peptide 1 (GLP-1) agonist and antidiabetic drug, has shown neuroprotective effects in animal models. In this study, we aimed to evaluate the safety and efficacy of liraglutide in mild to moderate Alzheimer’s disease syndrome. ‘Evaluating liraglutide …
Accès ouvert
2024
article
OpenAlex
Joseph Nowell, Grazia Daniela Femminella, Clive Holmes, Zuzana Walker et autres
Abstract Background Alzheimer’s disease is a devastating neurodegenerative disorder with a complex pathogenesis. One main pathological feature utilised in diagnosis is neurodegeneration or neuronal injury, which is reflected in reductions in cerebral glucose metabolism measured by [18F]Fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET). …
gb, nl
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Paul Edison, Grazia Daniela Femminella, Craig Ritchie, Joseph Nowell et autres
Abstract Background Preclinical evidence in transgenic models of Alzheimer’s disease (AD) suggests that liraglutide, a GLP1 analogue, exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and reducing insulin resistance, and increasing the proliferation of neuronal progenitor cells. ELAD is a …
gb, us, de, cn, nl
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Joseph Nowell, Megan M. Lacy Young, Grazia Daniela Femminella, Craig Ritchie et autres
Abstract Background Magnetic resonance spectroscopy (MRS) is a non‐invasive method of evaluating metabolite levels in the cerebral cortex. Measurable metabolites can provide markers of neuronal damage, glial activation and, neurotransmission, pathological features of Alzheimer’s disease. Here we sought to establish the effectiveness …
gb, nl
(code pays fourni par la source)
Accès ouvert
2023
article
OpenAlex
Joseph Nowell, Grazia Daniela Femminella, Craig Ritchie, Clive Holmes et autres
Abstract Background Glucose is the primary energy source required for the homeostatic function of the brain. Glucose transporter 1 (GLUT1) present at the blood‐brain barrier is a key regulator of glucose transport into the brain. Reduced GLUT1 expression is shown to exacerbate …
gb, nl
(code pays fourni par la source)
2021
article
OpenAlex
Paul Edison, Grazia Daniela Femminella, Craig Ritchie, Clive Holmes et autres
Abstract Background Liraglutide is a glucagon‐like peptide‐1 (GLP‐1) analogue licensed for the treatment of type 2 diabetes. Preclinical evidence in transgenic models of Alzheimer’s disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and cerebral glucose uptake, …
gb, de, cn, dk
(code pays fourni par la source)
Accès ouvert
2021
article
OpenAlex
Grazia Daniela Femminella, Nicholas R Livingston, Sanara Raza, Thalia van der Doef et autres
BACKGROUND: Type 2 diabetes is a risk factor for Alzheimer's disease (AD), and AD brain shows impaired insulin signalling. The role of peripheral insulin resistance on AD aetiopathogenesis in non-diabetic patients is still debated. Here we evaluated the influence of insulin resistance …
gb, cn, nl
(code pays fourni par la source)
Accès ouvert
2020
article
OpenAlex
Paul Edison, Sanara Raza, Grazia Daniela Femminella, Eleanor G Blunt et autres
Abstract Background Cerebral metabolic rate of glucose (CMRglc) can be measured with fluorodeoxyglucose (FDG) positron emission tomography (PET) using arterial blood sampling. However, blood sampling is an invasive methodology for subjects. Standard uptake value (SUV) is a non‐invasive method to assess the …
gb, nl
(code pays fourni par la source)
Accès ouvert
2020
article
OpenAlex
Paul Edison, Grazia Daniela Femminella, Joseph Nowell, Sanara Raza et autres
Abstract Background Brain atrophy can be reliably measured through volumetric analysis of structural MRI and is a valid biomarker of neurodegeneration in Alzheimer’s disease (AD) pathology1. The Alzheimer’s Disease Assessment Scale‐Cognitive subscale (ADAS‐Cog12) is a neuropsychological test designed to assess the level …
gb, nl
(code pays fourni par la source)
2020
article
OpenAlex
Paul Edison, Grazia Daniela Femminella, Nicholas R Livingston, Sanara Raza et autres
Abstract Background 18F‐fluorodeoxyglucose‐positron emission tomography (FDG‐PET) measures regional cerebral glucose metabolism –which is a biomarker of neuronal function in Alzheimer’s disease (AD) Neuropsychological measures such as the Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS‐Cog) – a measure of memory, language and …
gb, nl
(code pays fourni par la source)
2020
article
OpenAlex
Grazia Daniela Femminella, Thalia van der Doef, Stefan Carver, Clive Holmes et autres
Abstract Background Behavioral and psychological symptoms of dementia (BPSD) are highly prevalent in Alzheimer’s disease (AD) and associated with adverse outcomes. There is increasing interest in identifying the risk factors for developing BPSD among AD patients. However, the pathophysiological mechanisms underlying BPSD …
gb, nl
(code pays fourni par la source)